Certican 1 mg Norge - norsk - Statens legemiddelverk

certican 1 mg

novartis norge (2) - everolimus - tablett - 1 mg

Lestid 5 g Norge - norsk - Statens legemiddelverk

lestid 5 g

pfizer as - kolestipolhydroklorid - pulver i dosepose - 5 g

Paroxetin Hexal 20 mg Norge - norsk - Statens legemiddelverk

paroxetin hexal 20 mg

hexal a/s - paroksetinhydroklorid - tablett, filmdrasjert - 20 mg

Paroxetin Actavis 20 mg Norge - norsk - Statens legemiddelverk

paroxetin actavis 20 mg

actavis group ptc ehf (1) - paroksetinhydroklorid - tablett, filmdrasjert - 20 mg

Seroxat 20 mg Norge - norsk - Statens legemiddelverk

seroxat 20 mg

glaxosmithkline as - paroksetinhydrokloridhemihydrat - tablett, filmdrasjert - 20 mg

Seroxat 10 mg Norge - norsk - Statens legemiddelverk

seroxat 10 mg

glaxosmithkline as - paroksetinhydrokloridhemihydrat - tablett, filmdrasjert - 10 mg

Mektovi Den europeiske union - norsk - EMA (European Medicines Agency)

mektovi

pierre fabre medicament - binimetinib - melanom - antineoplastiske midler - binimetinib i kombinasjon med encorafenib er indisert for behandling av voksne pasienter med inoperabel eller metastatisk melanom med en braf v600 mutasjon.

Paroxetin Aristo 20 mg Norge - norsk - Statens legemiddelverk

paroxetin aristo 20 mg

aristo pharma gmbh - paroksetinhydrokloridhemihydrat - tablett, filmdrasjert - 20 mg

Rozlytrek Den europeiske union - norsk - EMA (European Medicines Agency)

rozlytrek

roche registration gmbh  - entrectinib - cancer; carcinoma, non-small-cell lung - antineoplastiske midler - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.

Tabrecta Den europeiske union - norsk - EMA (European Medicines Agency)

tabrecta

novartis europharm limited  - capmatinib dihydrochloride monohydrate - karsinom, ikke-småcellet lunge - antineoplastiske midler - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.